191 related articles for article (PubMed ID: 12718439)
1. Valproyl-CoA and esterified valproic acid are not found in brains of rats treated with valproic acid, but the brain concentrations of CoA and acetyl-CoA are altered.
Deutsch J; Rapoport SI; Rosenberger TA
Neurochem Res; 2003 Jun; 28(6):861-6. PubMed ID: 12718439
[TBL] [Abstract][Full Text] [Related]
2. Valproic acid selectively inhibits conversion of arachidonic acid to arachidonoyl-CoA by brain microsomal long-chain fatty acyl-CoA synthetases: relevance to bipolar disorder.
Bazinet RP; Weis MT; Rapoport SI; Rosenberger TA
Psychopharmacology (Berl); 2006 Jan; 184(1):122-9. PubMed ID: 16344985
[TBL] [Abstract][Full Text] [Related]
3. Chronic valproate does not alter the kinetics of docosahexaenoic acid within brain phospholipids of the unanesthetized rat.
Bazinet RP; Rao JS; Chang L; Rapoport SI; Lee HJ
Psychopharmacology (Berl); 2005 Oct; 182(1):180-5. PubMed ID: 15986187
[TBL] [Abstract][Full Text] [Related]
4. Studies on the extra-mitochondrial CoA -ester formation of valproic and Delta4 -valproic acids.
Aires CC; Ruiter JP; Luís PB; ten Brink HJ; Ijlst L; de Almeida IT; Duran M; Wanders RJ; Silva MF
Biochim Biophys Acta; 2007 Apr; 1771(4):533-43. PubMed ID: 17321204
[TBL] [Abstract][Full Text] [Related]
5. Chronic valproate treatment decreases the in vivo turnover of arachidonic acid in brain phospholipids: a possible common effect of mood stabilizers.
Chang MC; Contreras MA; Rosenberger TA; Rintala JJ; Bell JM; Rapoport SI
J Neurochem; 2001 May; 77(3):796-803. PubMed ID: 11331408
[TBL] [Abstract][Full Text] [Related]
6. The enzymatic basis for the metabolism and inhibitory effects of valproic acid: dehydrogenation of valproyl-CoA by 2-methyl-branched-chain acyl-CoA dehydrogenase.
Ito M; Ikeda Y; Arnez JG; Finocchiaro G; Tanaka K
Biochim Biophys Acta; 1990 May; 1034(2):213-8. PubMed ID: 2112956
[TBL] [Abstract][Full Text] [Related]
7. Valproyl CoA: an active metabolite of valproate?
Friel P
Med Hypotheses; 1990 Jan; 31(1):31-2. PubMed ID: 2156136
[TBL] [Abstract][Full Text] [Related]
8. Chronic carbamazepine decreases the incorporation rate and turnover of arachidonic acid but not docosahexaenoic acid in brain phospholipids of the unanesthetized rat: relevance to bipolar disorder.
Bazinet RP; Rao JS; Chang L; Rapoport SI; Lee HJ
Biol Psychiatry; 2006 Mar; 59(5):401-7. PubMed ID: 16182257
[TBL] [Abstract][Full Text] [Related]
9. CoA esters of valproic acid and related metabolites are oxidized in peroxisomes through a pathway distinct from peroxisomal fatty and bile acyl-CoA beta-oxidation.
Vamecq J; Vallee L; Fontaine M; Lambert D; Poupaert J; Nuyts JP
FEBS Lett; 1993 May; 322(2):95-100. PubMed ID: 8482393
[TBL] [Abstract][Full Text] [Related]
10. Influence of valproic acid on hepatic carbohydrate and lipid metabolism.
Becker CM; Harris RA
Arch Biochem Biophys; 1983 Jun; 223(2):381-92. PubMed ID: 6407400
[TBL] [Abstract][Full Text] [Related]
11. Formation of a free acyl adenylate during the activation of 2-propylpentanoic acid. Valproyl-AMP: a novel cellular metabolite of valproic acid.
Mao LF; Millington DS; Schulz H
J Biol Chem; 1992 Feb; 267(5):3143-6. PubMed ID: 1737769
[TBL] [Abstract][Full Text] [Related]
12. Hepatic hydrolysis of octanoyl-CoA and valproyl-CoA in control and valproate-fed animals.
Moore KH; Decker BP; Schreefel FP
Int J Biochem; 1988; 20(2):175-8. PubMed ID: 2895026
[TBL] [Abstract][Full Text] [Related]
13. Lithium and the other mood stabilizers effective in bipolar disorder target the rat brain arachidonic acid cascade.
Rapoport SI
ACS Chem Neurosci; 2014 Jun; 5(6):459-67. PubMed ID: 24786695
[TBL] [Abstract][Full Text] [Related]
14. A single therapeutic dose of valproate affects liver carbohydrate, fat, adenylate, amino acid, coenzyme A, and carnitine metabolism in infant mice: possible clinical significance.
Thurston JH; Carroll JE; Hauhart RE; Schiro JA
Life Sci; 1985 Apr; 36(17):1643-51. PubMed ID: 3921791
[TBL] [Abstract][Full Text] [Related]
15. Valproyl-dephosphoCoA: a novel metabolite of valproate formed in vitro in rat liver mitochondria.
Silva MF; Ijlst L; Allers P; Jakobs C; Duran M; de Almeida IT; Wanders RJ
Drug Metab Dispos; 2004 Nov; 32(11):1304-10. PubMed ID: 15483197
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and intramitochondrial levels of valproyl-coenzyme A metabolites.
Silva MF; Ruiter JP; IJlst L; Allers P; ten Brink HJ; Jakobs C; Duran M; Tavares de Almeida I; Wanders RJ
Anal Biochem; 2001 Mar; 290(1):60-7. PubMed ID: 11180937
[TBL] [Abstract][Full Text] [Related]
17. In vitro effects of valproate and valproate metabolites on mitochondrial oxidations. Relevance of CoA sequestration to the observed inhibitions.
Ponchaut S; van Hoof F; Veitch K
Biochem Pharmacol; 1992 Jun; 43(11):2435-42. PubMed ID: 1610408
[TBL] [Abstract][Full Text] [Related]
18. Effect of alpha-fluorination of valproic acid on valproyl-S-acyl-CoA formation in vivo in rats.
Grillo MP; Chiellini G; Tonelli M; Benet LZ
Drug Metab Dispos; 2001 Sep; 29(9):1210-5. PubMed ID: 11502730
[TBL] [Abstract][Full Text] [Related]
19. Valproate uncompetitively inhibits arachidonic acid acylation by rat acyl-CoA synthetase 4: relevance to valproate's efficacy against bipolar disorder.
Shimshoni JA; Basselin M; Li LO; Coleman RA; Rapoport SI; Modi HR
Biochim Biophys Acta; 2011 Mar; 1811(3):163-9. PubMed ID: 21184843
[TBL] [Abstract][Full Text] [Related]
20. Complete beta-oxidation of valproate: cleavage of 3-oxovalproyl-CoA by a mitochondrial 3-oxoacyl-CoA thiolase.
Silva MF; Ruiter JP; Overmars H; Bootsma AH; van Gennip AH; Jakobs C; Duran M; Tavares de Almeida I; Wanders RJ
Biochem J; 2002 Mar; 362(Pt 3):755-60. PubMed ID: 11879205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
